Fixed-dose combination of ertugliflozin and metformin hydrochloride for the treatment of type 2 diabetes

References

• DeFronzo RA. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58:773–795.
   PubMed Web of Science ®Google Scholar
• Schwartz S, Epstein S, Corkey BE, et al. The time is right for a new classification system for diabetes: rationale and implications of the β-cell–centric classification schema. Diabetes Care. 2016;39:179–186.
   PubMed Web of Science ®Google Scholar
• Davies MJ, D’Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. Sep 2018. doi:10.2337/dci18-0033.
   Web of Science ®Google Scholar
• Cahn A, Cefalu WT. Clinical considerations for use of initial combination therapy in type 2 diabetes. Diabetes Care. 2016;39:S137–S145.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. 8. Pharmacologic approached to glycemic treatment: standards of medical care in diabetes - 2018. Diabetes Care. 2018;41(Suppl. 1):S73–S85.
   PubMed Web of Science ®Google Scholar
• Garber AJ, Abrahamson MJ, Barzilay JI, et al. AACE/ACE comprehensive diabetes management algorithm 2015. Endocr Pract. 2016;22:84–113.
   PubMed Web of Science ®Google Scholar
• Bangalore S, Kamalakkannan G, Parkar S, et al. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Medicine. 2007;120:713–719.
   PubMed Web of Science ®Google Scholar
• Han S, Iglay K, Davies MJ, et al. Glycemic effectiveness and medication adherence with fixed-dose combination or coadministered dual therapy of antihyperglycemic regimens: a meta-analysis. Curr Med Res Opin. 2012;28:969–977.
   PubMed Web of Science ®Google Scholar
• Harris SB. The power of two: an update on fixed-dose combinations for type 2 diabetes. Expert Rev Clin Pharmacol. 2016;9:1453–1462.
   PubMed Web of Science ®Google Scholar
• Foretz M, Guigas B, Bertrand L, et al. Metformin: from mechanisms of action to therapies. Cell Metab. 2014;20:953–966.
   PubMed Web of Science ®Google Scholar
• Rena G, Hardie DG, Pearson ER. The mechanisms of action of metformin. Diabetologia. 2017;60:1577–1585.
   PubMed Web of Science ®Google Scholar
• SEGLUROMET™ (ertugliflozin and metformin hydrochloride), Prescribing Information. Whitehouse Station, NJ: Merck & Co., Inc.; 2017.
   Google Scholar
• Dash RP, Babu RJ, Srinivas NR. Comparative pharmacokinetics of three SGLT-2 inhibitors sergliflozin, remogliflozin and ertugliflozin: an overview. Xenobiotica. 2017;47:1015–1026.
   PubMed Web of Science ®Google Scholar
• Kalgutkar AS, Tugnait M, Zhu T, et al. Preclinical species and human disposition of PF-04971729, a selective inhibitor of the sodium-dependent glucose cotransporter 2 and clinical candidate for the treatment of type 2 diabetes mellitus. Drug Metab Dispos. 2011;39:1609–1619.
   PubMed Web of Science ®Google Scholar
• Miao Z, Nucci G, Amin N, et al. Pharmacokinetics, metabolism, and excretion of the antidiabetic agent ertugliflozin (PF-04971729) in healthy male subjects. Drug Metab Dispos. 2013;41:445–456.
   PubMed Web of Science ®Google Scholar
• Kumar V, Sahasrabudhe V, Matschke K, et al. Lack of a pharmacokinetic interaction between ertugliflozin and sitagliptin or metformin in healthy subjects. Poster presented at: ASCPT 2016 Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics; March 12; 2016; San Diego, CA
   Google Scholar
• Sahasrabudhe V, Saur D, Matschke K, et al. A Phase 1, randomized, placebo‐ and active‐controlled crossover study to determine the effect of single‐dose ertugliflozin on QTc interval in healthy volunteers. Clin Pharmacol Drug Dev. 2018;7:513–523.
   PubMed Web of Science ®Google Scholar
• Idris I, Donnelly R. Sodium-glucose co-transporter-2 inhibitors: an emerging new class of oral antidiabetic drug. Diabetes Obes Metab. 2009;11:79–88.
   PubMed Web of Science ®Google Scholar
• Amin NB, Wang X, Jain SM, et al. Dose‐ranging efficacy and safety study of ertugliflozin, a sodium‐glucose co‐transporter 2 inhibitor, in patients with type 2 diabetes on a background of metformin. Diabetes Obes Metab. 2015;17:591–598.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Frias J, Páll D, et al. Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET). Diabetes Obes Metab. 2018;20:520–529.
   PubMed Web of Science ®Google Scholar
• Pratley RE, Eldor R, Raji A, et al. Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: the VERTIS FACTORIAL randomized trial. Diabetes Obes Metab. 2018;20:1111–1120.
   PubMed Web of Science ®Google Scholar
• Dagogo-Jack S, Liu J, Eldor R, et al. Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: the VERTIS SITA2 placebo-controlled randomized study. Diabetes Obes Metab. 2018;20:530–540.
   PubMed Web of Science ®Google Scholar
• Hollander P, Liu J, Hill J, et al. Ertugliflozin compared with glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin: the VERTIS SU randomized study. Diabetes Ther. 2018;9:193–207.
   PubMed Web of Science ®Google Scholar
• GLUCOPHAGE (metformin hydrochloride), Prescribing Information. Princeton, NJ: Bristol-Myers Squibb Company; 2018.
   Google Scholar
• US Food and Drug Administration Safety Announcement. FDA warns about rare occurrences of a serious infection of the genital area with SGLT2 inhibitors for diabetes. [cited 2018 Sept 5]. Available from: https://www.fda.gov/Drugs/DrugSafety/ucm617360.htm
   Google Scholar
• Monami M, Nardini C, Mannucci E. Efficacy and safety of sodium glucose co‐transport‐2 inhibitors in type 2 diabetes: a meta‐analysis of randomized clinical trials. Diabetes Obes Metab. 2014;16:457–466.
   PubMed Web of Science ®Google Scholar
• Monami M, Nreu B, Zannoni S, et al. Effects of SGLT-2 inhibitors on diabetic ketoacidosis: A meta-analysis of randomised controlled trials. Diabetes Res Clin Pract. 2017;130:53–60.
   PubMed Web of Science ®Google Scholar
• Neal B, Perkovic V, Mahaffey KW, et al. for the CANVAS program collaborative group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644–657.
   PubMed Web of Science ®Google Scholar
• Cha SA, Park YM, Yun JS, et al. A comparison of effects of DPP-4 inhibitor and SGLT2 inhibitor on lipid profile in patients with type 2 diabetes. Lipids Health Dis. 2017;16:58.
   PubMed Web of Science ®Google Scholar
• US food and drug administration approval letter. [cited 2018 Sept 5]. Available from: https://www.accessdata.fda.gov
   Google Scholar
• European medicines agency authorization. [cited 2018 Sept 5]. Available from: http://www.ema.europa.eu
   Google Scholar
• Health Canada regulatory decision summary. [cited 2018 Sept 5]. Available from: https://hpr-rps.hres.ca
   Google Scholar
• Australian therapeutic goods administration approval. [cited 2018 Sept 5]. Available from: www.ebs.tga.gov.au
   Google Scholar
• Grunberger G, Camp S, Johnson J, et al. Ertugliflozin in patients with stage 3 chronic kidney disease and type 2 diabetes mellitus: the VERTIS RENAL randomized study. Diabetes Ther. 2018;9:49–66.
   PubMed Web of Science ®Google Scholar
• Centers for disease control and prevention. National Diabetes Statistics Report, 2017. Atlanta, GA: Centers for Disease Control and Prevention, U.S. Dept of Health and Human Services; 2017
   Google Scholar
• Khunti K, Wolden ML, Thorsted BL, et al. Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people. Diabetes Care. 2013;36:3411–3417.
   PubMed Web of Science ®Google Scholar
• Khunti K, Nikolajsen A, Thorsted BL, et al. Clinical inertia with regard to intensifying therapy in people with type 2 diabetes treated with basal insulin. Diabetes Obes Metab. 2016;18:401–409.
   PubMed Web of Science ®Google Scholar
• Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–2128.
   PubMed Web of Science ®Google Scholar
• Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311–322.
   PubMed Web of Science ®Google Scholar
• Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834–1844.
   PubMed Web of Science ®Google Scholar
• van Baar MJB, van Ruiten CC, Muskiet MHA, et al. SGLT2 Inhibitors in combination therapy: from mechanisms to clinical considerations in type 2 diabetes management. Diabetes Care. 2018;41:1543–1556.
   PubMed Web of Science ®Google Scholar
• Frias JP, Guja C, Hardy E, et al. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol. 2016;4:1004–1016.
   PubMed Web of Science ®Google Scholar
• Jabbour SA, Frìas JP, Hardy E, et al. Safety and efficacy of exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy: 52-Week results of the DURATION-8 randomized controlled trial. Diabetes Care. 2018;41:2136–2146.
   PubMed Web of Science ®Google Scholar
• Ludvik B, Frias JP, Tinahones FJ, et al. Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2018;6:370–381.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. [cited 2018 Sept 5]. Available from: clinicaltrials.gov/ct2/show/NCT01986881
   Google Scholar
• Cannon CP, McGuire D, Pratley R, et al. Design and baseline characteristics of the evaluation of ertugliflozin efficacy and safety cardiovascular outcomes trial (VERTIS-CV). J Am Coll Cardiol. 2018;71(Issue11 Supplement):1212–1406. Presentation Number.
   Google Scholar
• Majewski C, Bakris GL. Blood pressure reduction: an added benefit of sodium–glucose cotransporter 2 inhibitors in patients with type 2 diabetes. Diabetes Care. 2015;38:429–430.
   PubMed Web of Science ®Google Scholar
• Sumida Y, Yoneda M. Current and future pharmacological therapies for NAFLD/NASH. J Gastroenterol. 2018;53:362–376.
   PubMed Web of Science ®Google Scholar
• Sanofi press release. [cited 2018 Sept 5]. Available from: http://www.news.sanofi.us/2018-05-22-FDA-to-review-Zynquista-TM-sotagliflozin-as-potential-treatment-for-type-1-diabetes
   Google Scholar